André P Abbes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
André P Abbes has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
H Engel
5 shared publicationsA A M Franken
2 shared publicationsE J M Bruggeman
2 shared publicationsA A Franken
1 shared publicationA.L.M. Strunk
1 shared publication- Annuska Strunk
Department of Clinical Chemistry and Neonatal Screening, Isala Hospital, Dokter van Heesweg 2, 8025 AB Zwolle, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 15 May 2019
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 5 (2) , 21
Validation of a Fast, Robust, Inexpensive, Two-Tiered Neonatal Screening Test algorithm on Dried Blood Spots for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is one of the leading genetic causes of infant mortality with an incidence of 1:10,000. The recently-introduced antisense oligonucleotide treatment improves the outcome of this disease, in particular when applied at an early stage of progression. The genetic cause of SMA is, in >95% of cases, a homozygous deletion of the survival motor neuron 1 (SMN1) gene, which makes the low-cost detection of SMA cases as part of newborn screening programs feasible. We developed and validated a new SALSA MC002 melting curve assay that detects the absence of the SMN1 exon 7 DNA sequence without detecting asymptomatic carriers and reliably discriminates SMN1 from its genetic homolog SMN2 using crude extracts from newborn screening cards. Melting curve analysis shows peaks specific for both the SMN1 gene and the disease modifying SMN2 homolog. The detection of the SMN2 homolog, of which the only clinically relevant difference from the SMN1 gene is a single nucleotide in exon 7, was only used to confirm a correct reaction in samples that lacked the SMN1 gene, and not for SMN2 quantification. We retrieved 47 DBS samples from children with genetically-confirmed SMA, after informed consent from parents, and 375 controls from the national archive of the Dutch National Institute for Public Health and the Environment (RIVM). The assay correctly identified all anonymized and randomized SMA and control samples (i.e., sensitivity and specificity of 100%), without the detection of carriers, on the three most commonly-used PCR platforms with melting curve analysis. This test’s concordance with the second-tier ‘golden standard’ P021 SMA MLPA test was 100%. Using the new P021–B1 version, crude extracts from DBS cards could also be used to determine the SMN2 copy number of SMA patients with a high level of accuracy. The MC002 test showed the feasibility and accuracy of SMA screening in a neonatal screening program.
- 15 May 2019
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 5 (2) , 21
Open AccessValidation of a Fast, Robust, Inexpensive, Two-Tiered Neonatal Screening Test algorithm on Dried Blood Spots for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is one of the leading genetic causes of infant mortality with an incidence of 1:10,000. The recently-introduced antisense oligonucleotide treatment improves the outcome of this disease, in particular when applied at an early stage of progression. The genetic cause of SMA is, in >95% of cases, a homozygous deletion of the survival motor neuron 1 (SMN1) gene, which makes the low-cost detection of SMA cases as part of newborn screening programs feasible. We developed and validated a new SALSA MC002 melting curve assay that detects the absence of the SMN1 exon 7 DNA sequence without detecting asymptomatic carriers and reliably discriminates SMN1 from its genetic homolog SMN2 using crude extracts from newborn screening cards. Melting curve analysis shows peaks specific for both the SMN1 gene and the disease modifying SMN2 homolog. The detection of the SMN2 homolog, of which the only clinically relevant difference from the SMN1 gene is a single nucleotide in exon 7, was only used to confirm a correct reaction in samples that lacked the SMN1 gene, and not for SMN2 quantification. We retrieved 47 DBS samples from children with genetically-confirmed SMA, after informed consent from parents, and 375 controls from the national archive of the Dutch National Institute for Public Health and the Environment (RIVM). The assay correctly identified all anonymized and randomized SMA and control samples (i.e., sensitivity and specificity of 100%), without the detection of carriers, on the three most commonly-used PCR platforms with melting curve analysis. This test’s concordance with the second-tier ‘golden standard’ P021 SMA MLPA test was 100%. Using the new P021–B1 version, crude extracts from DBS cards could also be used to determine the SMN2 copy number of SMA patients with a high level of accuracy. The MC002 test showed the feasibility and accuracy of SMA screening in a neonatal screening program.
- 1 June 2011
- Published by Dustri-Verlag Dr. Karl Feistle in Nieren- und Hochdruckkrankheiten
- Vol. 40 (6) , 250-269
Ein Leitfaden zur Diagnose genetischer Defekte als Ursache von Nierenversagen: Eine Literaturübersicht
- 1 June 2011
- Published by Dustri-Verlag Dr. Karl Feistle in Nieren- und Hochdruckkrankheiten
- Vol. 40 (6) , 250-269
Ein Leitfaden zur Diagnose genetischer Defekte als Ursache von Nierenversagen: Eine Literaturübersicht
- 1 February 2006
- Vol. 118 (6) , 783
Gene symbol: AVP. Disease: Diabetes insipidus, neurohypophyseal. Accession #Hm0558.
- 1 February 2006
- Vol. 118 (6) , 783
Gene symbol: AVP. Disease: Diabetes insipidus, neurohypophyseal. Accession #Hm0558.
- 1 February 2006
- Vol. 118 (6) , 783
Gene symbol: AVP. Disease: Diabetes insipidus, neurohypophyseal. Accession #Hm0559.
- 1 February 2006
- Vol. 118 (6) , 783
Gene symbol: AVP. Disease: Diabetes insipidus, neurohypophyseal. Accession #Hm0559.
- 1 February 2006
- Vol. 118 (6) , 783
Gene symbol: AVP. Disease: Diabetes insipidus, neurohypophyseal. Accession #Hm0560.
- 1 February 2006
- Vol. 118 (6) , 783
Gene symbol: AVP. Disease: Diabetes insipidus, neurohypophyseal. Accession #Hm0560.
- 1 February 2006
- Vol. 118 (6) , 784
Gene symbol: AVP. Disease: Diabetes insipidus, neurohypophyseal. Accession #Hm0561.
- 1 February 2006
- Vol. 118 (6) , 784
Gene symbol: AVP. Disease: Diabetes insipidus, neurohypophyseal. Accession #Hm0561.
- Open Access
- 1 October 2000
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 46 (10) , 1699-1702
Identification of Two Distinct Mutations at the Same Nucleotide Position, Concomitantly with a Novel Polymorphism in the Vasopressin-Neurophysin II Gene (AVP-NP II) in Two Dutch Families with Familial Neurohypophyseal Diabetes Insipidus
Familial neurohypophyseal diabetes insipidus (FNDI) is a rare autosomal dominant inherited disease, characterized by serious polyuria and polydipsia, caused by deficient neurosecretion of the antidiuretic hormone, arginine vasopressin (AVP). Vasopressin is a hormone that affects peripherally and centrally regulated functions such as antidiuresis and blood pressure regulation in peripheral tissues and temperature regulation in the central nervous system ( 1). The antidiuretic function of AVP controls the serum osmolality by stimulating renal water resorption ( 1)( 2). In patients with FNDI, there is insufficient release of AVP, leading to insufficient stimulation of renal water resorption ( 1)( 3)( 4)( 5). Often, these patients have a constant feeling of thirst that leads to an excessive water intake to compensate for the high urinary output.
- 1 October 2000
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 46 (10) , 1699-1702
Open AccessIdentification of Two Distinct Mutations at the Same Nucleotide Position, Concomitantly with a Novel Polymorphism in the Vasopressin-Neurophysin II Gene (AVP-NP II) in Two Dutch Families with Familial Neurohypophyseal Diabetes Insipidus
Familial neurohypophyseal diabetes insipidus (FNDI) is a rare autosomal dominant inherited disease, characterized by serious polyuria and polydipsia, caused by deficient neurosecretion of the antidiuretic hormone, arginine vasopressin (AVP). Vasopressin is a hormone that affects peripherally and centrally regulated functions such as antidiuresis and blood pressure regulation in peripheral tissues and temperature regulation in the central nervous system ( 1). The antidiuretic function of AVP controls the serum osmolality by stimulating renal water resorption ( 1)( 2). In patients with FNDI, there is insufficient release of AVP, leading to insufficient stimulation of renal water resorption ( 1)( 3)( 4)( 5). Often, these patients have a constant feeling of thirst that leads to an excessive water intake to compensate for the high urinary output.
- 13 May 2000
- Vol. 144 (20) , 941-5
[Identification of a new mutation (CysII6Gly) in a family with neurogenic diabetes insipidus].
Elucidation and identification of the molecular biological alteration in the arginine-vasopressin neurophysin II AVP-NPII gene in a family with familial neurohypophysial diabetes insipidus (FNDI). Descriptive. Following the finding of diabetes insipidus in a 2-year-old boy and his father a molecular genetic investigation was performed in the Isala Klinieken, Sophia location, in Zwolle, the Netherlands, to determine the nature of a possible gene mutation. Thereafter the AVP-NPII gene was screened in the family with polymerase chain reaction (PCR) and restriction enzyme analysis on DNA isolated from peripheral blood. An extensive pedigree was made. A new mutation in the AVP-NPII gene was identified in the part encoding the transport peptide neurophysin II. in exon 3, on codon 116, in which thymine was replaced by guanine, leading to the amino acid glycine instead of cysteine in the gene product. In a Dutch family with familial neurohypophysial diabetes insipidus a new gene mutation was found (CysII6Gly). Clarification of the molecular background of FNDI in this family made it possible to test family members in a relatively simple and friendly way (without the thirsting test) by PCR and restriction enzyme analysis for the presence of the mutation and the predisposition for diabetes insipidus.
- 13 May 2000
- Vol. 144 (20) , 941-5
[Identification of a new mutation (CysII6Gly) in a family with neurogenic diabetes insipidus].
Elucidation and identification of the molecular biological alteration in the arginine-vasopressin neurophysin II AVP-NPII gene in a family with familial neurohypophysial diabetes insipidus (FNDI). Descriptive. Following the finding of diabetes insipidus in a 2-year-old boy and his father a molecular genetic investigation was performed in the Isala Klinieken, Sophia location, in Zwolle, the Netherlands, to determine the nature of a possible gene mutation. Thereafter the AVP-NPII gene was screened in the family with polymerase chain reaction (PCR) and restriction enzyme analysis on DNA isolated from peripheral blood. An extensive pedigree was made. A new mutation in the AVP-NPII gene was identified in the part encoding the transport peptide neurophysin II. in exon 3, on codon 116, in which thymine was replaced by guanine, leading to the amino acid glycine instead of cysteine in the gene product. In a Dutch family with familial neurohypophysial diabetes insipidus a new gene mutation was found (CysII6Gly). Clarification of the molecular background of FNDI in this family made it possible to test family members in a relatively simple and friendly way (without the thirsting test) by PCR and restriction enzyme analysis for the presence of the mutation and the predisposition for diabetes insipidus.